The cardiovascular outcome trials LEADER and SUSTAIN-6 for liraglutide and semaglutide, respectively, have shown a significant cardiovascular disease (CVD) risk reduction on top of standard of care in people with type 2 diabetes (T2D), at increased risk of CVD in addition to control of glycaemia. 1,2 The improved cardiovascular risk profile has been suggested to be attributed-at least partly-to the anti-inflammatory properties of these long-acting glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) independently of weight loss. 3-5 However, the physiological and cellular mechanism behind the CVD benefit has not yet been fully uncovered. Using the ApoE−/− and the Ldlr−/− mouse models of atherosclerosis, liraglutide has been demonstrated to result
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.